Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD40L confers helper functions to human intra-melanoma class-I-restricted CD4+CD8+ double positive T cells.
Parrot T, Oger R, Benlalam H, Raingeard de la Blétière D, Jouand N, Coutolleau A, Preisser L, Khammari A, Dréno B, Guardiola P, Delneste Y, Labarrière N, Gervois N. Parrot T, et al. Among authors: benlalam h. Oncoimmunology. 2016 Oct 28;5(12):e1250991. doi: 10.1080/2162402X.2016.1250991. eCollection 2016. Oncoimmunology. 2016. PMID: 28123891 Free PMC article.
IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
Parrot T, Allard M, Oger R, Benlalam H, Raingeard de la Blétière D, Coutolleau A, Preisser L, Desfrançois J, Khammari A, Dréno B, Labarrière N, Delneste Y, Guardiola P, Gervois N. Parrot T, et al. Among authors: benlalam h. Eur J Immunol. 2016 Jul;46(7):1770-82. doi: 10.1002/eji.201546061. Epub 2016 May 6. Eur J Immunol. 2016. PMID: 27094152 Free article.
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.
Frazao A, Colombo M, Fourmentraux-Neves E, Messaoudene M, Rusakiewicz S, Zitvogel L, Vivier E, Vély F, Faure F, Dréno B, Benlalam H, Bouquet F, Savina A, Pasmant E, Toubert A, Avril MF, Caignard A. Frazao A, et al. Among authors: benlalam h. Cancer Immunol Res. 2017 Jul;5(7):582-593. doi: 10.1158/2326-6066.CIR-16-0380. Epub 2017 Jun 2. Cancer Immunol Res. 2017. PMID: 28576831
Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma.
Samimi M, Benlalam H, Aumond P, Gaboriaud P, Fradin D, Kervarrec T, Florenceau L, Vignard V, Blom A, Touzé A, Gervois N, Labarriere N. Samimi M, et al. Among authors: benlalam h. Cell Immunol. 2019 Oct;344:103961. doi: 10.1016/j.cellimm.2019.103961. Epub 2019 Aug 1. Cell Immunol. 2019. PMID: 31472938
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.
Ducoin K, Oger R, Bilonda Mutala L, Deleine C, Jouand N, Desfrançois J, Podevin J, Duchalais E, Cruard J, Benlalam H, Labarrière N, Bossard C, Jarry A, Gervois-Segain N. Ducoin K, et al. Among authors: benlalam h. Oncoimmunology. 2022 Mar 9;11(1):2046931. doi: 10.1080/2162402X.2022.2046931. eCollection 2022. Oncoimmunology. 2022. PMID: 35295095 Free PMC article.
Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity.
Ollier J, Kervarrec T, Samimi M, Benlalam H, Aumont P, Vivien R, Touzé A, Labarrière N, Vié H, Clémenceau B. Ollier J, et al. Among authors: benlalam h. Cancer Immunol Immunother. 2018 Aug;67(8):1209-1219. doi: 10.1007/s00262-018-2176-2. Epub 2018 May 28. Cancer Immunol Immunother. 2018. PMID: 29808366 Free PMC article.
21 results